Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RUXOLITINIB Cause Osteonecrosis? 113 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 113 reports of Osteonecrosis have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.2% of all adverse event reports for RUXOLITINIB.

113
Reports of Osteonecrosis with RUXOLITINIB
0.2%
of all RUXOLITINIB reports
18
Deaths
59
Hospitalizations

How Dangerous Is Osteonecrosis From RUXOLITINIB?

Of the 113 reports, 18 (15.9%) resulted in death, 59 (52.2%) required hospitalization, and 7 (6.2%) were considered life-threatening.

Is Osteonecrosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 113 reports have been filed with the FAERS database.

What Other Side Effects Does RUXOLITINIB Cause?

Off label use (12,492) Death (6,561) Fatigue (5,663) Anaemia (3,593) Haemoglobin decreased (3,297) Platelet count decreased (3,028) Diarrhoea (2,531) Asthenia (2,529) Dizziness (2,398) Pneumonia (2,343)

What Other Drugs Cause Osteonecrosis?

EMTRICITABINE\TENOFOVIR DISOPROXIL (8,935) TENOFOVIR DISOPROXIL (7,182) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (4,338) COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL (2,081) EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL (1,492) PREDNISONE (779) PREDNISOLONE (711) DENOSUMAB (567) METHOTREXATE (563) DEXAMETHASONE (531)

Which RUXOLITINIB Alternatives Have Lower Osteonecrosis Risk?

RUXOLITINIB vs SABRIL RUXOLITINIB vs SACCHAROMYCES CEREVISIAE RUXOLITINIB vs SACITUZUMAB GOVITECAN RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY RUXOLITINIB vs SACROSIDASE

Related Pages

RUXOLITINIB Full Profile All Osteonecrosis Reports All Drugs Causing Osteonecrosis RUXOLITINIB Demographics